EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Arginase 1 deficiency: a treatable form of spastic paraplegia

Alessandro Burlina, Anna Ardissone, Roberta Battini, Alberto Burlina, Serena Gasperini, Andrea Pession, Francesco Porta, Carlo Dionisi Vici

Neurological Sciences · 2025

DOI: 10.1007/s10072-025-08153-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurological Sciences, 2025. Verfasst von Alessandro Burlina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Medicine, Neurology Unit, St. Bassiano Hospital, Via dei Lotti 40, 36061, Bassano del Grappa, Italy. alessandro.burlina@aulss7.veneto.it. Hauptthemen laut MEDLINE: Hyperargininemia, Arginase, Spastic Paraplegia, Hereditary. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Immedica Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Arginase 1 deficiency (ARG1-D) is a rare hereditary urea cycle disorder characterized by elevated arginine levels, resulting in progressive neurological impairment and severe physical and cognitive disability. Due to its low prevalence, overlapping symptoms with other neurological disorders, and current limitations in newborn screening tools, ARG1-D is often misdiagnosed or diagnosed late, limiting access to early interventions.

Aim

This review and expert opinion aim to provide an overview of the clinical manifestations, diagnostic challenges, and treatment options for ARG1-D, offering a practical resource for specialists to recognize this rare, progressive, yet treatable disease.

Results

ARG1-D typically presents with progressive spastic paraplegia, developmental delays, cognitive impairment, and seizures, with symptom onset and severity varying by age. Differential diagnoses mainly include hereditary spastic paraplegia, cerebral palsy, and hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, each with distinct clinical features and biochemical markers. Potential red flags for ARG1-D include elevated plasma arginine levels, spasticity, seizures, and cognitive impairment. These should prompt further examinations to confirm the diagnosis, which is based on biochemical assays for hyperargininemia and on genetic testing. Once confirmed, early treatment is advised, including dietary protein restriction, ammonia scavengers, antiepileptic drugs, and novel therapies, such as pegzilarginase, which targets the disease’s metabolic root.

Conclusion

Experts stress the importance of increased awareness of ARG1-D characteristics, noting that early recognition and treatment are crucial to patient outcomes. Greater recognition of ARG1-D’s distinctive features, differential diagnosis, and diagnostic tools, even among non-specialist clinicians, could help prevent misdiagnoses and facilitate the identification of this rare yet treatable condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperargininemiaArginaseSpastic Paraplegia, HereditaryHumans

Stichwörter der Autor:innen

Arginase 1 deficiencyDifferential diagnosisNeurological impairmentSpastic paraplegiaUrea cycle disorder

Substanzen

Arginase

Autor:innen und Institutionen

  • Dept. of Medicine, Neurology Unit, St. Bassiano Hospital, Via dei Lotti 40, 36061, Bassano del Grappa, Italy. alessandro.burlina@aulss7.veneto.it.
  • Child Neurology Unit, Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Neuroscience, IRCCS Stella Maris Foundation, Calambrone, Pisa, Italy.
  • Division of Inherited Metabolic Diseases, Department of Woman's and Child's Health, University Hospital, 35129, Padua, Italy.
  • Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

Förderung

  • Immedica Pharma

Zitieren

APA

Burlina, A., Ardissone, A., Battini, R., Burlina, A., Gasperini, S., Pession, A., Porta, F., & Vici, C. D. (2025). Arginase 1 deficiency: a treatable form of spastic paraplegia. Neurological Sciences. https://doi.org/10.1007/s10072-025-08153-3

Vancouver

Burlina A, Ardissone A, Battini R, Burlina A, Gasperini S, Pession A, et al. Arginase 1 deficiency: a treatable form of spastic paraplegia. Neurological Sciences. 2025. doi:10.1007/s10072-025-08153-3

BibTeX
@article{Burlina2025,
  author = {Burlina, Alessandro and Ardissone, Anna and Battini, Roberta and Burlina, Alberto and Gasperini, Serena and Pession, Andrea and Porta, Francesco and Vici, Carlo Dionisi},
  title = {Arginase 1 deficiency: a treatable form of spastic paraplegia},
  journal = {Neurological Sciences},
  year = {2025},
  doi = {10.1007/s10072-025-08153-3}
}
Kostenlos starten →